STOCK TITAN

Jonathan P. Biller sells shares; Vertex Pharmaceuticals (NASDAQ: VRTX) Form 144

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Jonathan P. Biller reported sales of Common stock under Rule 144. The filing lists sales of 12/03/2025 ($155,803 for 347 shares), 02/11/2026 ($886,327.75 for 1,925 shares), 02/13/2026 ($493,012 for 988 shares) and 02/17/2026 ($1,211,902.96 for 2,476 shares).

The form also shows a Restricted Stock Vesting entry dated 02/17/2026 with a numeric reference of 1,244, listed under "Securities To Be Sold" with the method described as Compensation.

Positive

  • None.

Negative

  • None.

Insights

Routine insider sales disclosed under Rule 144; amounts and dates are explicit.

The filing records multiple open-market dispositions by Jonathan P. Biller, with aggregate proceeds visible across four dated entries. Each sale line lists the share count and corresponding dollar proceeds, providing a clear transaction record.

These are disclosed sales activity; their investment impact depends on total holdings and timing not shown here. Subsequent filings or company disclosures would be needed to assess any change in beneficial ownership.

Restricted stock vesting item is noted, tied to compensation on 02/17/2026.

The excerpt includes a "Restricted Stock Vesting" entry dated 02/17/2026 with a numeric value of 1,244 under "Securities To Be Sold" and the distribution method labeled Compensation. This suggests recent vesting activity.

Timing and whether vested shares were sold or retained are not detailed beyond the listed sale lines; further filings would clarify cash‑flow treatment and post‑vesting ownership.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What sales did Jonathan P. Biller report in the Form 144 for VRTX?

He reported four sales: 347, 1,925, 988, and 2,476 shares on 12/03/2025, 02/11/2026, 02/13/2026, and 02/17/2026, respectively, with corresponding proceeds shown for each line.

How much proceeds were reported for the February 17, 2026 sale?

The filing lists proceeds of $1,211,902.96 for the sale on 02/17/2026. That amount is shown alongside the 2,476 shares reported sold on that date in the excerpt.

Does the Form 144 show any restricted stock activity for VRTX?

Yes, the excerpt shows a Restricted Stock Vesting entry dated 02/17/2026 with a numeric reference of 1,244 under "Securities To Be Sold" and the method labeled Compensation.

Who is the broker or intermediary listed on the Form 144?

The excerpt lists Fidelity Brokerage Services LLC at 900 Salem Street, Smithfield RI as the broker of record in the filing metadata shown in the document.

Are the sales reported in the Form 144 part of recent three‑month activity?

Yes, the filing groups these entries under "Securities Sold During The Past 3 Months," showing the four dated sales from 12/03/2025 through 02/17/2026 with share counts and proceeds listed.
Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Latest SEC Filings

VRTX Stock Data

119.21B
253.14M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON